Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMI Y HADDAD

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1710072624
CMS profile
77195
Location
OAK LAWN, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,828.47

211 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,113.49 208
Consulting Fee $525.00 1
Education $189.98 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMI Y HADDAD

NPI 1710072624 · CMS profile ID 77195

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OAK LAWN, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710072624?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710072624?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710072624?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 211 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1710072624?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

211 matching records · $4,828.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 211 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 211.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $20.5307/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842621 CMS
TAIHO ONCOLOGY, INC. $25.6806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137938032 CMS
Daiichi Sankyo Inc. $7.3806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429806 CMS
Kite Pharma, Inc. $16.6806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612805 CMS
Novartis Pharmaceuticals Corporation $26.6606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842623 CMS
Eisai Inc. $15.7906/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110774893 CMS
Janssen Biotech, Inc. $20.8906/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599867 CMS
Regeneron Healthcare Solutions, Inc. $33.8206/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062635 CMS
Daiichi Sankyo Inc. $17.0706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429804 CMS
Lilly USA, LLC $25.5606/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135359864 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.1506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086267093 CMS
E.R. Squibb & Sons, L.L.C. $102.4006/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101361740 CMS
Novartis Pharmaceuticals Corporation $16.0806/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842617 CMS
PFIZER INC. $28.9006/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131343750 CMS
AstraZeneca Pharmaceuticals LP $23.1205/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104724299 CMS
Aveo Pharmaceuticals, Inc. $33.7905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143484793 CMS
Novartis Pharmaceuticals Corporation $27.7405/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842615 CMS
Regeneron Healthcare Solutions, Inc. $10.9805/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062633 CMS
Merck Sharp & Dohme LLC $25.5205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141893526 CMS
Novartis Pharmaceuticals Corporation $8.6805/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842619 CMS
PFIZER INC. $24.8205/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131655625 CMS
Janssen Biotech, Inc. $8.5605/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078600174 CMS
SOBI, INC $16.9405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141416814 CMS
AstraZeneca Pharmaceuticals LP $23.2505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105621851 CMS
Regeneron Healthcare Solutions, Inc. $7.8705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062627 CMS
Regeneron Healthcare Solutions, Inc. $1.0305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062629 CMS
Regeneron Healthcare Solutions, Inc. $13.5505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062631 CMS
PFIZER INC. $10.1005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131653478 CMS
Daiichi Sankyo Inc. $19.2305/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089429802 CMS
Janssen Pharmaceuticals, Inc $9.0805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078011568 CMS
Merck Sharp & Dohme LLC $22.3005/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141942347 CMS
Janssen Biotech, Inc. $89.9905/02/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078599817 CMS
BeiGene USA, Inc. $21.1805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120859665 CMS
Incyte Corporation $99.9905/01/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141206923 CMS
E.R. Squibb & Sons, L.L.C. $11.3904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101361736 CMS
Tempus AI, Inc $25.3404/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150165808 CMS
SERVIER PHARMACEUTICALS LLC $20.4704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147262795 CMS
ABBVIE INC. $19.0104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103859431 CMS
ARRAY BIOPHARMA INC $7.1404/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131569875 CMS
AstraZeneca Pharmaceuticals LP $28.2704/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104556688 CMS
Novartis Pharmaceuticals Corporation $8.3504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842613 CMS
EMD Serono, Inc. $13.8704/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120227318 CMS
ABBVIE INC. $20.5204/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103859429 CMS
Genentech USA, Inc. $18.0304/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133092774 CMS
GlaxoSmithKline, LLC. $32.1304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116492461 CMS
GlaxoSmithKline, LLC. $15.5604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116400960 CMS
Lilly USA, LLC $26.0904/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135368914 CMS
Regeneron Healthcare Solutions, Inc. $22.8204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114062625 CMS
Novartis Pharmaceuticals Corporation $20.8004/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842611 CMS
Novartis Pharmaceuticals Corporation $16.4404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086842601 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,298.33 195
PY2020 $2,854.97 150
PY2021 $10,020.51 190
PY2022 $8,283.12 201
PY2023 $9,239.25 205
PY2024 $4,828.47 211
PY2025 $4,801.01 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $296,277.60 45
PY2024 Principal investigator $240,615.11 35
PY2023 Principal investigator $454,295.09 196
PY2022 Principal investigator $143,765.80 37
PY2021 Recipient $2,614.20 1
PY2021 Principal investigator $182,879.65 54
PY2020 Principal investigator $77,734.59 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233737007
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,408.63 12/31/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS, LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190309130
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233737005
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233737003
Principal investigator 1 PFIZER INC. $956.00 10/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228714196
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736983
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 09/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941970
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 09/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942004
Principal investigator 1 PFIZER INC. $1,125.00 09/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228748587
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736985
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736987
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941959
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942021
Principal investigator 1 PFIZER INC. $956.00 07/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745734
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,400.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185542464
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736989
Principal investigator 1 PFIZER INC. $1,125.00 06/30/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228784289
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941913
Principal investigator 1 AstraZeneca UK Limited $4,000.00 06/06/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185542462
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736991
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $55,547.00 05/12/2025 Non-covered Recipient Entity
Affiliated Oncologists, Llc
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235999201
Principal investigator 1 Mirati Therapeutics, Inc. $23,625.00 05/02/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530400
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,750.00 04/30/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185542458
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736993
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941926
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941947
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 04/15/2025 Non-covered Recipient Entity
Affiliated Oncologists
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942032
Principal investigator 1 PFIZER INC. $956.00 04/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228747580
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736995
Principal investigator 1 Mirati Therapeutics, Inc. $120,670.85 03/28/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530394
Principal investigator 1 Amgen Inc. $133.36 03/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS, LLC
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246638911
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Affiliated Oncologists Llc Ste 109
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941936
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Affiliated Oncologists Llc Ste 109
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941993
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 02/28/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736997
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233736999
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,000.00 02/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185542460
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
Affiliated Oncologists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233737001
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,664.43 01/27/2025 Non-covered Recipient Entity
Affiliated Oncologists, Llc
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235999203
Principal investigator 1 Amgen Inc. $2,550.00 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS, LLC
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) No dispute reported 06/30/2026 1246638907
Principal investigator 1 AstraZeneca Pharmaceuticals LP $510.00 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS, LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185542456
Principal investigator 1 AstraZeneca Pharmaceuticals LP $380.00 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS, LLC
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185542466
Principal investigator 1 Eli Lilly and Company $316.63 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS - SOUTHLAND ONCOLOGY
Not supplied No dispute reported 06/30/2026 1187873223
Principal investigator 1 Eli Lilly and Company $956.00 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS - SOUTHLAND ONCOLOGY
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187880191
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 01/15/2025 Non-covered Recipient Entity
Affiliated Oncologists Llc Ste 109
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941981
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
AFFILIATED ONCOLOGISTS LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746721